What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?

Bartsch, Sarah M.; Asti, Lindsey; Cox, Sarah N; Durham, David P.; Randall, Samuel; Hotez, Peter J.; Galvani, Alison P.; Lee, Bruce Y.

doi:10.1093/infdis/jiy688

Cited by 9 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they do not show the effect in risk groups nor assume herd immunity from previous outbreaks as we did; Durham et al (2018) showed that immunizing females aged 9 to 49 years with a 75% effective vaccine and a coverage of 90%, would reduce the incidence of prenatal infections by at least 94% [41]. Similarly, Bartsch et al (2018) showed that women of childbearing age or young adults would be an ideal target group for vaccination [42]. Valega-Mackenzie et al (2018) formulated a vaccination model for ZIKV transmission that included mosquito and sexual transmission [43].…”

Section: Interpretation In Comparison With Other Studiesmentioning

confidence: 58%

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

et al. 2019

View full text Add to dashboard Cite

The 2015-2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infection, followed by protective immunity. The timing and burden of the next Zika virus outbreak remains unclear. We used an agent-based model to simulate the dynamics of age-specific immunity to ZIKV, and predict the future age-specific risk using data from Managua, Nicaragua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong immunity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. The imbalance in age-specific immunity implies that people in the 15-29 age range will be at highest risk of infection during the next ZIKV outbreak, increasing the expected number of congenital abnormalities. ZIKV vaccine development and licensure are urgent to attain the maximum benefit in reducing the population-level risk of infection and the risk of adverse congenital outcomes. This urgency increases if immunity is not lifelong.

show abstract

Section: Interpretation In Comparison With Other Studiesmentioning

confidence: 58%

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, DNA vaccines are relatively easy and cost-effective to manufacture on a large scale. They have excellent safety profiles for women of childbearing age and children, both critical target populations to prevent and mitigate ZIKV outbreaks ( 62 ) .…”

Section: Discussionmentioning

confidence: 99%

NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice

et al. 2019

View full text Add to dashboard Cite

The causal association of Zika virus (ZIKV) with microcephaly, congenital malformations in infants, and Guillain-Barré syndrome in adults highlights the need for effective vaccines. Thus far, efforts to develop ZIKV vaccines have focused on the viral envelope. ZIKV NS1 as a vaccine immunogen has not been fully explored, although it can circumvent the risk of antibody-dependent enhancement of ZIKV infection, associated with envelope antibodies. Here, we describe a novel DNA vaccine encoding a secreted ZIKV NS1, that confers rapid protection from systemic ZIKV infection in immunocompetent mice. We identify novel NS1 T cell epitopes in vivo and show that functional NS1-specific T cell responses are critical for protection against ZIKV infection. We demonstrate that vaccine-induced anti-NS1 antibodies fail to confer protection in the absence of a functional T cell response. This highlights the importance of using NS1 as a target for T cell–based ZIKV vaccines.

show abstract

“…Computational models have helped quantify the potential impact of and guide decision making for epidemics and outbreaks in the past, such as the 2009 H1N1 pandemic, [6][7][8][9][10][11][12][13][14][15][16] the ongoing Ebola outbreak that emerged in 2018, 17 and the 2015-2016 Zika outbreak. 18,19 Therefore, we developed a computational model to represent what may happen to each patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and quantify potential resource use and direct medical costs (i.e., costs directly attributable to health care resource use for interventions and care that are specific to COVID-19 illness and would typically be paid out by third-party payers) in the U.S. under various conditions.…”

mentioning

confidence: 99%

The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States

et al. 2020

View full text Add to dashboard Cite

With the coronavirus disease 2019 pandemic, one of the major concerns is the burden COVID-19 will impose on the United States (U.S.) health care system. We developed a Monte Carlo simulation model representing the U.S. population and what can happen to each person who gets infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). We estimate resource use and direct medical costs per infection and at the national level, with various "attack rates" (infection rates) to understand the potential economic benefits of reducing the burden of the disease. A single symptomatic COVID-19 infection would cost a median of $3,045 in direct medical costs incurred only during the course of the infection. Eighty percent of the U.S. population getting infected could result in a median of 44.6 million hospitalizations, 10.7 million ICU admissions, 6.5 million ventilators used, and 249.5 million hospital bed days, costing $654.0 billion in direct costs over the course of the pandemic. If 20% were to become infected, there would be a median of 11.2 million hospitalizations, 62.3 million hospital bed days, and 1.6 million ventilators used, costing $163.4 billion.

show abstract

What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?

Cited by 9 publications

References 23 publications

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice

The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States

Contact Info

Product

Resources

About